Acquisition by Paul Goode of 796 shares of GlucoTrack subject to Rule 16b-3
| GCTK Stock | USD 5.83 0.19 3.16% |
About 62% of GlucoTrack's investor base is looking to short. The analysis of overall sentiment of trading GlucoTrack stock suggests that many investors are alarmed at this time. GlucoTrack's investing sentiment shows overall attitude of investors towards GlucoTrack.
GlucoTrack | Build AI portfolio with GlucoTrack Stock |
Filed transaction by GlucoTrack Director, Officer: Chief Executive Officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
GlucoTrack Fundamental Analysis
We analyze GlucoTrack's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GlucoTrack using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GlucoTrack based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Ratio
Current Ratio Comparative Analysis
GlucoTrack is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
GlucoTrack Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with GlucoTrack stock to make a market-neutral strategy. Peer analysis of GlucoTrack could also be used in its relative valuation, which is a method of valuing GlucoTrack by comparing valuation metrics with similar companies.
Peers
GlucoTrack Related Equities
| DRMA | Dermata Therapeutics | 9.46 | ||||
| ACON | Aclarion | 5.71 | ||||
| STSS | Sharps Technology | 1.52 | ||||
| NXGL | Nexgel | 1.17 | ||||
| CXAI | CXApp | 1.06 | ||||
| LUCY | Innovative Eyewear | 1.99 | ||||
| ZJYL | JIN MEDICAL | 3.03 |
Check out GlucoTrack Hype Analysis, GlucoTrack Correlation and GlucoTrack Performance. For more information on how to buy GlucoTrack Stock please use our How to buy in GlucoTrack Stock guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Medical Equipment space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlucoTrack. If investors know GlucoTrack will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlucoTrack listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of GlucoTrack is measured differently than its book value, which is the value of GlucoTrack that is recorded on the company's balance sheet. Investors also form their own opinion of GlucoTrack's value that differs from its market value or its book value, called intrinsic value, which is GlucoTrack's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlucoTrack's market value can be influenced by many factors that don't directly affect GlucoTrack's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlucoTrack's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlucoTrack is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlucoTrack's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.